Nifty
:
24273.80
Sensex
:
80334.81
-140.60 (-0.58%)
-411.97 (-0.51%)
Nifty
Sensex
:
:
24273.80
80334.81
-140.60 (-0.58%)
-411.97 (-0.51%)

Glenmark Pharmaceuticals Ltd.

Pharmaceuticals & Drugs - Global

Rating :
N/A

BSE: 532296 | NSE: GLENMARK

NSE BSE
1499.85
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1495.40
  •  1516.00
  •  1485.45
  •  1493.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  462007
  •  6932.51
  •  1830.95
  •  985.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 39,953.99
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 39,695.40
  • 0.18%
  • 4.54

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.65%
  • 2.18%
  • 12.32%
  • FII
  • DII
  • Others
  • 23.15%
  • 13.33%
  • 2.37%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.87
  • 2.11
  • -1.35

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -0.16
  • -6.78
  • -12.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.76
  • 30.71
  • 37.27

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 14.28
  • 13.70
  • 10.83

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.64
  • 2.54
  • 2.90

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 10.36
  • 10.48
  • 11.87

Earnings Forecasts:

Description
2024
2025
2026
2027
Adj EPS
-53.22
51.34
63.08
78.17
P/E Ratio
29.66
24.14
19.48
Revenue
11635
13720
15227
17066
EBITDA
1244
2551
2980
3549
Net Income
-1502
1450
1791
2222
ROA
-8.9
11.8
13.5
16
P/B Ratio
5.47
4.72
4
3.36
ROE
-17.34
17.63
18.41
19.07
FCFF
-1663.44
-193
1184.24
1717.94
FCFF Yield
-3.91
-0.45
2.79
4.04

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
3,387.55
2,506.70
35.14%
3,433.80
3,207.38
7.06%
3,244.19
3,036.07
6.85%
3,062.95
3,000.51
2.08%
Expenses
2,787.32
2,715.35
2.65%
2,831.88
2,745.09
3.16%
2,655.97
2,598.71
2.20%
2,558.61
2,602.60
-1.69%
EBITDA
600.23
-208.65
-
601.91
462.28
30.20%
588.21
437.35
34.49%
504.34
397.91
26.75%
EBIDTM
17.72%
-8.32%
17.53%
14.41%
18.13%
14.41%
16.47%
13.26%
Other Income
31.13
45.41
-31.45%
39.42
1.70
2,218.82%
31.49
19.72
59.69%
773.16
-42.42
-
Interest
52.29
134.34
-61.08%
48.48
121.46
-60.09%
39.58
111.61
-64.54%
148.56
109.14
36.12%
Depreciation
122.74
147.07
-16.54%
120.28
141.45
-14.97%
117.79
142.04
-17.07%
151.34
135.02
12.09%
PBT
456.33
-521.38
-
472.57
-124.35
-
462.33
151.40
205.37%
530.83
-688.40
-
Tax
108.30
-71.80
-
118.09
55.95
111.06%
122.10
113.72
7.37%
1,769.47
-138.90
-
PAT
348.03
-449.58
-
354.49
-180.30
-
340.24
37.68
802.97%
-1,238.65
-549.49
-
PATM
10.27%
-17.94%
10.32%
-5.62%
10.49%
1.24%
-40.44%
-18.31%
EPS
12.33
-12.45
-
12.55
-2.90
-
12.06
5.31
127.12%
-43.17
-15.18
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Net Sales
13,128.49
11,813.10
11,583.24
12,304.90
10,943.93
10,640.97
9,865.47
9,074.42
9,079.41
7,561.67
6,680.94
Net Sales Growth
11.73%
1.98%
-5.86%
12.44%
2.85%
7.86%
8.72%
-0.05%
20.07%
13.18%
 
Cost Of Goods Sold
4,259.93
4,352.00
4,204.38
4,312.08
3,620.18
3,623.78
3,283.71
2,963.32
2,552.03
2,246.58
1,538.25
Gross Profit
8,868.56
7,461.10
7,378.85
7,992.82
7,323.75
7,017.18
6,581.76
6,111.10
6,527.39
5,315.09
5,142.69
GP Margin
67.55%
63.16%
63.70%
64.96%
66.92%
65.94%
66.72%
67.34%
71.89%
70.29%
76.98%
Total Expenditure
10,833.78
10,617.77
9,948.23
9,984.60
8,859.55
8,942.89
8,279.67
7,459.05
7,042.71
6,124.52
5,466.62
Power & Fuel Cost
-
124.00
111.75
200.64
164.67
173.69
165.25
137.47
127.02
120.47
109.11
% Of Sales
-
1.05%
0.96%
1.63%
1.50%
1.63%
1.68%
1.51%
1.40%
1.59%
1.63%
Employee Cost
-
2,868.14
2,600.78
2,447.42
2,343.71
2,254.78
2,056.07
1,871.84
1,640.81
1,378.19
1,212.61
% Of Sales
-
24.28%
22.45%
19.89%
21.42%
21.19%
20.84%
20.63%
18.07%
18.23%
18.15%
Manufacturing Exp.
-
813.30
633.51
784.63
638.74
669.50
725.16
648.59
546.75
956.59
1,323.66
% Of Sales
-
6.88%
5.47%
6.38%
5.84%
6.29%
7.35%
7.15%
6.02%
12.65%
19.81%
General & Admin Exp.
-
1,313.59
1,212.13
1,264.86
1,027.60
1,168.32
891.10
526.29
1,022.89
491.20
253.29
% Of Sales
-
11.12%
10.46%
10.28%
9.39%
10.98%
9.03%
5.80%
11.27%
6.50%
3.79%
Selling & Distn. Exp.
-
1,092.27
1,137.20
896.31
943.21
1,005.63
1,125.08
996.99
1,064.70
892.67
991.23
% Of Sales
-
9.25%
9.82%
7.28%
8.62%
9.45%
11.40%
10.99%
11.73%
11.81%
14.84%
Miscellaneous Exp.
-
54.46
48.49
78.68
121.44
47.19
33.29
314.55
88.52
38.82
991.23
% Of Sales
-
0.46%
0.42%
0.64%
1.11%
0.44%
0.34%
3.47%
0.97%
0.51%
0.58%
EBITDA
2,294.69
1,195.33
1,635.01
2,320.30
2,084.38
1,698.08
1,585.80
1,615.37
2,036.70
1,437.15
1,214.32
EBITDA Margin
17.48%
10.12%
14.12%
18.86%
19.05%
15.96%
16.07%
17.80%
22.43%
19.01%
18.18%
Other Income
875.20
839.99
288.90
166.67
50.22
159.60
208.14
91.40
37.37
20.00
6.88
Interest
288.91
515.97
349.04
298.10
353.11
377.32
334.58
285.57
237.32
178.88
190.15
Depreciation
512.15
581.91
569.17
486.71
443.55
417.17
325.90
301.88
264.37
234.28
300.41
PBT
1,922.06
937.45
1,005.70
1,702.16
1,337.93
1,063.20
1,133.45
1,119.33
1,572.38
1,043.98
730.63
Tax
2,117.96
1,867.35
329.40
447.60
412.39
320.11
375.64
315.46
382.68
300.94
334.07
Tax Rate
110.19%
5117.43%
137.34%
31.06%
29.83%
29.20%
28.88%
28.18%
25.66%
28.83%
61.46%
PAT
-195.89
-1,899.00
-169.72
941.71
970.04
775.97
924.98
803.78
1,108.80
743.23
209.54
PAT before Minority Interest
-200.21
-1,830.85
-89.56
993.65
970.09
775.97
924.99
803.87
1,108.75
743.04
209.47
Minority Interest
-4.32
-68.15
-80.16
-51.94
-0.05
0.00
-0.01
-0.09
0.05
0.19
0.07
PAT Margin
-1.49%
-16.08%
-1.47%
7.65%
8.86%
7.29%
9.38%
8.86%
12.21%
9.83%
3.14%
PAT Growth
0.00%
-
-
-2.92%
25.01%
-16.11%
15.08%
-27.51%
49.19%
254.70%
 
EPS
-6.94
-67.29
-6.01
33.37
34.37
27.50
32.78
28.48
39.29
26.34
7.43

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Shareholder's Funds
7,847.93
9,473.92
9,086.65
7,064.63
6,070.51
5,605.18
5,163.48
4,492.52
3,629.64
1,783.49
Share Capital
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
28.22
27.13
Total Reserves
7,801.48
9,428.09
9,042.13
7,014.78
6,028.59
5,566.35
5,124.75
4,462.86
3,599.98
1,756.36
Non-Current Liabilities
-357.23
2,621.45
1,269.61
2,803.62
3,033.01
2,279.94
2,824.12
3,257.81
1,499.40
2,749.09
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
3,852.14
2,571.74
3,888.82
4,042.99
3,573.75
4,141.78
4,536.34
2,487.30
2,574.38
Long Term Provisions
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Liabilities
5,818.59
4,546.24
4,689.43
4,201.02
4,125.98
4,021.09
3,287.89
2,702.68
3,999.25
3,776.71
Trade Payables
2,535.93
2,000.43
2,288.66
2,237.77
2,125.84
2,220.75
1,869.78
1,743.22
1,940.79
1,948.04
Other Current Liabilities
1,517.23
1,605.31
1,446.27
885.78
1,001.63
1,013.21
690.60
509.32
1,137.01
1,264.30
Short Term Borrowings
833.36
350.00
370.00
513.01
442.60
303.02
295.04
187.19
787.42
347.60
Short Term Provisions
932.08
590.51
584.50
564.45
555.91
484.11
432.46
262.95
134.03
216.78
Total Liabilities
13,308.91
17,006.95
15,397.16
14,068.92
13,229.11
11,905.83
11,275.12
10,452.59
9,127.99
8,309.10
Net Block
4,210.16
5,421.76
5,887.25
5,128.85
5,028.56
3,670.25
3,029.55
2,755.09
2,593.55
2,015.38
Gross Block
9,619.64
10,359.59
10,213.47
8,731.58
8,269.83
6,527.27
5,367.95
4,769.92
4,300.54
3,495.47
Accumulated Depreciation
5,409.48
4,937.83
4,326.23
3,602.73
3,241.28
2,857.01
2,338.39
2,014.83
1,706.99
1,480.09
Non Current Assets
5,880.82
6,840.24
7,114.82
6,709.33
6,425.49
5,209.02
4,286.43
3,577.96
3,223.69
2,978.04
Capital Work in Progress
661.88
1,189.64
1,009.87
1,381.67
1,221.89
1,398.94
1,121.87
708.11
542.79
477.13
Non Current Investment
789.66
44.57
49.62
24.63
24.59
29.66
14.66
15.69
17.20
17.12
Long Term Loans & Adv.
211.70
180.80
161.38
146.29
123.97
94.36
119.78
98.94
69.99
468.16
Other Non Current Assets
7.42
3.46
6.70
27.89
26.49
15.80
0.56
0.13
0.16
0.27
Current Assets
7,428.08
8,423.64
8,282.35
7,359.58
6,803.62
6,696.82
6,988.69
6,874.64
5,904.30
5,331.06
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
2,513.05
2,373.62
2,499.83
2,276.83
2,135.62
2,252.07
2,030.59
2,139.05
1,567.76
1,269.04
Sundry Debtors
1,858.41
3,665.17
3,101.14
2,572.05
2,408.96
2,194.59
2,331.81
2,404.32
2,492.65
2,511.76
Cash & Bank
1,659.46
1,160.30
1,411.52
1,139.16
1,111.24
937.76
1,234.69
1,057.66
857.12
775.88
Other Current Assets
1,397.16
316.61
297.46
671.05
1,147.78
1,312.40
1,391.61
1,273.61
986.77
774.38
Short Term Loans & Adv.
1,218.95
907.93
972.41
700.49
544.48
547.18
580.83
590.22
594.89
742.94
Net Current Assets
1,609.49
3,877.39
3,592.92
3,158.56
2,677.63
2,675.73
3,700.80
4,171.96
1,905.05
1,554.35
Total Assets
13,308.90
15,263.88
15,397.17
14,068.91
13,229.11
11,905.84
11,275.12
10,452.60
9,127.99
8,309.10

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Cash From Operating Activity
-265.44
625.39
1,108.65
1,131.21
1,392.41
1,324.17
1,648.05
657.43
344.85
481.68
PBT
569.19
868.45
1,441.25
1,382.47
1,096.08
1,300.63
1,119.33
1,491.43
1,043.98
543.54
Adjustment
1,009.81
1,471.96
787.11
644.82
636.23
329.83
571.28
726.56
391.03
522.76
Changes in Working Capital
-796.95
-1,074.48
-561.26
-385.84
127.06
136.34
309.06
-861.51
-611.96
-266.82
Cash after chg. in Working capital
782.05
1,265.93
1,667.09
1,641.45
1,859.37
1,766.81
1,999.67
1,356.48
823.05
799.49
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,047.49
-640.54
-558.44
-510.24
-466.95
-442.63
-351.61
-699.05
-478.20
-317.81
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
4,560.89
-528.49
-333.28
-675.24
-783.52
-698.99
-1,013.34
-712.35
-880.17
-540.04
Net Fixed Assets
-234.42
-220.67
-155.36
-184.89
-248.78
455.14
-362.24
-256.09
-286.93
-1,354.84
Net Investments
-2,632.08
-1,773.32
-1,569.44
-2,276.02
-1,445.18
-56.07
-1,345.98
-8.28
-198.90
-250.28
Others
7,427.39
1,465.50
1,391.52
1,785.67
910.44
-1,098.06
694.88
-447.98
-394.34
1,065.08
Cash from Financing Activity
-3,906.13
-77.46
-520.49
-441.78
-444.66
-738.74
-468.50
543.15
698.60
199.22
Net Cash Inflow / Outflow
389.32
19.45
254.88
14.20
164.23
-113.56
166.21
488.24
163.27
140.86
Opening Cash & Equivalents
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74
794.80
Closing Cash & Equivalent
1,658.27
1,443.03
1,410.53
1,138.10
1,110.28
936.28
1,233.36
1,056.36
857.12
763.74

Financial Ratios

Consolidated /

Standalone
Description
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Book Value (Rs.)
277.46
335.13
321.45
249.60
214.65
198.27
182.62
159.16
128.59
65.74
ROA
-11.86%
-0.54%
6.74%
7.11%
6.17%
7.98%
7.40%
11.33%
8.52%
2.58%
ROE
-21.18%
-0.97%
12.33%
14.81%
13.32%
17.21%
16.67%
27.31%
27.46%
8.79%
ROCE
4.88%
4.43%
14.19%
15.30%
14.04%
16.47%
14.77%
20.54%
18.53%
12.40%
Fixed Asset Turnover
2.77
2.74
2.94
2.97
1.44
1.66
1.80
2.03
1.96
1.90
Receivable days
36.38
43.76
37.24
36.01
78.95
83.73
94.95
97.29
119.39
125.97
Inventory Days
32.19
31.52
31.35
31.90
75.25
79.22
83.59
73.65
67.68
59.42
Payable days
190.23
186.18
191.57
219.98
98.44
97.43
96.28
101.59
117.03
95.22
Cash Conversion Cycle
-121.67
-110.90
-122.98
-152.06
55.77
65.53
82.26
69.35
70.04
90.17
Total Debt/Equity
0.13
0.46
0.40
0.67
0.80
0.80
0.90
1.05
1.10
2.13
Interest Cover
1.07
1.69
5.83
4.92
3.90
4.89
4.92
7.28
6.84
3.86

Annual Reports:

FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015

News Update:


  • Glenmark Pharmaceuticals’ arm to launch generic Adderall tablets
    17th Apr 2025, 12:21 PM

    The company will begin distribution in May 2025

    Read More
  • Glenmark Pharmaceuticals’ arm recalls over 25 products in US market
    14th Apr 2025, 11:16 AM

    It is also recalling products like Voriconazole Tablets, Lacosamide Tablets, Frovatriptan Succinate Tablets and Rufinamide Tablets

    Read More
  • Glenmark’s US arm recalling 8,160 bottles of chlorpromazine hydrochloride tablets in US
    11th Apr 2025, 15:08 PM

    The company initiated the Class II nationwide (US) recall on March 11, 2025

    Read More
  • Glenmark’s US arm launches Vancomycin Hydrochloride for injection USP
    1st Apr 2025, 10:07 AM

    The Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of around $39.3 million

    Read More
  • Glenmark’s US arm gets USFDA’s approval for Olopatadine Hydrochloride Ophthalmic Solution
    21st Mar 2025, 09:35 AM

    Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the U.S. by Glenmark Therapeutics Inc., USA

    Read More
  • Glenmark Pharmaceuticals launches Empagliflozin in India
    12th Mar 2025, 13:00 PM

    These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk

    Read More
  • Glenmark Pharmaceuticals’ arm launches Polyethylene Glycol 3350
    10th Mar 2025, 09:35 AM

    The MiraLAX Powder for Solution, 17 grams (OTC) market achieved annual sales of approximately $555.7 million

    Read More
  • Glenmark Pharmaceuticals’ US arm recalls around 14.76 lakh bottles of Atomoxetine Capsules
    3rd Mar 2025, 10:25 AM

    The company is recalling the affected lot due to ‘CGMP Deviations’

    Read More
  • Glenmark Pharmaceuticals’ arm acquires, launches Acetylcysteine Injection
    3rd Mar 2025, 09:22 AM

    Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA Inc

    Read More
  • Glenmark Pharmaceuticals’ US arm launches Epinephrine Injection
    27th Feb 2025, 09:08 AM

    The company’s Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug

    Read More
  • Glenmark Pharmaceuticals turns black in Q3
    17th Feb 2025, 16:41 PM

    Total consolidated income of the company increased by 33.96% at Rs 3418.68 crore for Q3FY25

    Read More
  • Glenmark Pharma - Quarterly Results
    14th Feb 2025, 18:19 PM

    Read More
  • Glenmark Pharmaceuticals’ US arm launches Latanoprost Ophthalmic Solution
    14th Feb 2025, 10:30 AM

    The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million

    Read More
  • Glenmark Pharmaceuticals’ US arm launches Clindamycin Phosphate Foam, 1%
    12th Feb 2025, 10:08 AM

    According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.